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Abstract 
Background: Despite left ventricular (LV) dysfunction contributing to mortality in chronic heart 
failure (HF), the molecular mechanisms of LV failure continues to remain poorly understood and 
myocardial biomarkers have yet to be identified. The aim of this pilot study was to investigate 
specific transcriptome changes occurring in cardiac tissues of patients with HF compared to healthy 
condition patients to improve diagnosis and possible treatment of affected subjects.  
Methods: Unlike other studies, only dilated cardiomyopathy (DCM) (n = 2) and restrictive 
cardiomyopathy (RCM) (n = 2) patients who did not report family history of the disease were 
selected with the aim of obtaining a homogeneous population for the study. The transcriptome of all 
patients were studied by RNA-sequencing (RNA-Seq) and the read counts were adequately filtered 
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and normalized using a recently developed user-friendly tool for RNA-Seq data analysis, based on a 
new Graphical User Interface (RNA-SeqGUI). 
Results: By using this approach in a pairwise comparison with healthy donors, we were able to 
identify DCM- and RCM-specific expression signatures for protein-coding genes as well as for long 
non-coding RNAs (lncRNAs). Differential expression of 5 genes encoding different members of the 
mediator complex was disclosed in this analysis. Interestingly, a significant alteration was found  
for genes which had never been associated with HF until now, and 27 lncRNA/mRNA pairs that 
were significantly altered in HF patients.  
Conclusions: The present findings revealed specific expression pattern of both protein-coding and 
lncRNAs in HF patients, confirming that new LV myocardial biomarkers could be reliably 
identified using Next-Generation Sequencing-based approaches. 
Key words: cardiovascular disease, heart failure, ncRNA, mediator complex, RNA-
sequencing 
 
 
Introduction  
Cardiomyopathies are a heterogeneous group of myocardial diseases resulting in cardiac 
dysfunction, which are clinically manifested with heart failure (HF). With the rapid evolution of 
molecular genetics in cardiology, the knowledge and literature of the complex interplay between 
genetics and cardiomyopathies have significantly expanded over the past few decades. Inherited 
cardiomyopathies include a wide spectrum of clinical phenotypes, which classically include dilated 
cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), 
and others [1]. DCM is characterized by an increase in both left ventricular (LV) mass and volume 
with thinning and stretching of LV wall [1]. HCM is characterized by inappropriate myocardial 
hypertrophy (without identifiable etiology such as hypertension, aortic stenosis or other 
contributing factors), interstitial fibrosis, myofiber disarray, disorganized myocardial architecture 
and impaired LV performance [1]. RCM is a heart-muscle disease resulting in impaired ventricular 
filling with normal or decreased diastolic volume of either or both ventricles [1]. However, one 
phenotypic pattern may progress to another, or many others may manifest as more than one 
phenotype [2]. HF is a multi-factorial condition occurring in about 2–3% of the adult population [2–
4]. The main cause is coronary artery disease (CAD) and it is a consequence of myocardial 
infarction (MI) [2–4]. The onset and progression of HF are closely related to several molecular and 
cellular alterations. 
 3 
In recent years, advances in drug treatment have significantly improved the prognosis of HF 
patients. However, there are still several limitations on the benefits of medical therapy for patients 
with refractory end-stage disease, which often require mechanical support or heart transplantation. 
Thus, the development of novel and effective therapeutic treatments for HF is a major challenge 
today and requires a detailed knowledge of HF molecular pathogenesis.  
Global gene expression profiling comparing disease vs. a healthy condition is a valuable 
approach for discovering new potential biomarkers for diagnosis/prediction of disease severity and 
for identifying novel drug targets. Particularly, whole-transcriptome analysis is increasingly 
acquiring a key role in the knowledge of mechanisms responsible for complex diseases, elucidating 
the involvement of multiple genes and pathways in pathological mechanisms.  
Over the last decade, global gene expression analysis using microarrays has been widely 
applied to cardiovascular research [5, 6]. Most transcriptome studies on MI have been performed in 
rodents due to higher accessibility to homogenous populations and myocardial tissue at defined 
stages of the disease [5, 6]. Although gene expression studies have elucidated many crucial 
molecular alterations involved in HF pathophysiology, they do not fully capture the complexity of 
human transcriptome [7]. Human myocardial tissue is difficult to obtain and usually comes from 
heterogeneous patient cohorts, generally in late-stage cardiomyopathies of different etiologies 
leading to HF. Despite these limitations, global gene expression analysis using microarrays has 
been widely applied to the field of cardiovascular research. However, although gene expression 
studies have elucidated many crucial molecular alterations involved in HF pathophysiology, they 
could not fully capture the complexity of human transcriptome [7]. The introduction of RNA-
Sequencing (RNA-Seq) has overcome some drawbacks of previously used technologies, allowing a 
simultaneous investigation of different layers of transcriptome complexity at an in-depth level of 
resolution [8, 9]. Indeed, RNA-Seq analysis revealed alterations of cytoskeletal and 
nucleocytoplasmic transport-related genes, as well as of other key pathways in HF [7–12]. 
Interestingly, several studies have also highlighted the importance of noncoding RNAs (ncRNAs) in 
failing human hearts [13, 14]. Currently, the best-characterized ncRNAs in the heart are the 
microRNAs (miRNAs), which finely modify mRNA expression through post-transcriptional 
silencing. Recently, several miRNAs have been found to be associated with cardiovascular disease 
(CVD) [13]. Functional analyses have demonstrated that several dysregulated miRNAs may exert 
either positive or negative regulatory effects on cardiac hypertrophic pathways. Indeed, miR-1, 
miR-133, miR-378, miR-185 and miR-155 showed anti-hypertrophic effects [15–18]; while miR-
208 family, miR-212/132, miR-23 and miR-199 promoted hypertrophy in cardiomyocytes [19, 20]. 
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Unlike miRNAs, long noncoding RNAs (lncRNAs) are much less well characterized, and how they 
function in biology and gene regulation remains an attractive area of investigation [14].  
In the last several years, some lncRNAs have been identified and their function has been 
implicated in different biological processes. However, only a few lncRNAs were associated to 
cardiomyopathy and heart biology, as myosin heavy chain-associated RNA transcript (MHRT) [21]. 
It is a cluster of lncRNAs transcribed from the MYH7 gene that encodes the βMHC protein. MHRT 
expression is heart specific and it is expressed at low levels in the fetal heart, increasing in the adult 
heart. Furthermore, higher levels of lincRNA predicting cardiac remodeling (LIPCAR) in plasma 
from HF patients following ICM were independently associated with an elevated risk for future 
cardiovascular death and predictive for LV remodeling [22]. This effect was also reported for 
ANRIL, KCNQ1OT1, MIAT, and MALAT1 in a cohort of 414 MI patients [23]. Nevertheless, the 
specific functions of these transcripts within the heart or vascular tissue remain relatively unknown. 
Moreover, ANRIL was shown to be highly expressed in atherosclerotic plaques and might be an 
accurate regulator in the inflammatory nuclear factor kappa B (NF-κB) pathway [24]. Therefore, 
the importance of the altered expression of lncRNAs in human HF induces exploration of their 
putative involvement and functional roles in myocardial disease [24]. 
In this pilot study, a systematic transcriptome analysis was performed, by RNA-Seq on 
myocardial tissue specimens from HF patients vs. healthy donors (HD) in order to reveal evidence 
of a distinctive expression network signature in end-stage HF diseased hearts. This approach may 
offer important insights into the complex pathogenesis of advanced cardiac failure, as well as for 
identifying potential targets for therapeutic intervention. Initially highlighted were classic heart 
disease-associated coding and noncoding genes, whose expression was significantly altered as 
MYH6, MYH7 and MHRT. Then, differentially expressed genes (DEGs) were screened and their 
possible roles in the pathogenesis of HF were explored by using multiple bioinformatics methods to 
identify specific transcriptomic signatures.  
 
Methods  
Patients and tissue samples collection 
This study was performed according to the principles outlined in the Helsinki Declaration, 
and was approved by the local Ethics Committee. Eight heart biopsies were collected from heart 
transplantation candidates. The diagnosis of HF (DCM, n = 2; and RCM n = 2) was determined by 
medical history, pathological and instrumental examination. LV tissue specimens (n = 4 for organ 
donors and n = 4 for recipients) were acquired during surgical intervention at the “Monaldi” 
Hospital. Cardiac tissue samples were harvested and snap frozen in liquid nitrogen at the time of 
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cardiac surgery. Clinical features of patients are shown in Table 1.  
 
RNA extraction, library preparation and sequencing 
Heart tissue samples were homogenized by Tissue Lyser Disruption system (Qiagen) and 
total RNA was isolated with TRIzol Reagent (Invitrogen) according to manufacturer protocol. 
cDNA library preparation was performed starting from 4 µg of total RNA using Illumina TruSeq 
Libraries and then sequenced at high coverage on the Illumina HiSeq2000 NGS platform available 
at Tigem Institute in Pozzuoli (Naples) [25]. (RNA integrity and quality are detailed in 
Supplementary Methods — see journal website). 
 
RNA-Seq data analysis 
The quality control on raw reads was performed using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). High-quality reads were mapped to 
the human reference transcriptome (Ensembl v70) and to human reference genome (GRCh37/hg19) 
using TopHat2 v2.0.10 [26]. Only unique mapped reads were used to quantify gene expression in 
each sample.  Gene expression as reads counts were estimated after filtering (Proportion test 
implemented in NOISeqBio package in R) and normalization of raw reads counts using RNA-
SeqGUI developed in R language [27]. Principal component analysis (PCA), MA and density plots 
were generated using the graphical user interface (GUI). Differential expression between patients 
was evaluated using the non-parametric NOISeqBIO function [28] implemented in RNA-SeqGUI. 
A posterior probability (PP) > 0.95 was used to determine DEGs. RNA-Seq datasets were submitted 
to GEO public resource and the accession number to the data files is GSE71613 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71613).  
 
Gene ontology and pathway analysis 
The Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.ad.jp/kegg/) 
[29] is an authoritative database containing a variety of biochemical pathways. In addition, the 
Database for Annotation, Visualization and Integration Discovery (DAVID) 
(https://david.ncifcrf.gov) [30] is a gene functional classification tool that organizes and condenses 
abundant heterogeneous annotation content. Functional enrichment analysis was conducted in order 
to recognize the DEG enriched biochemical pathways using KEGG database, gene ontology (GO) 
associated biological functions and PANTHER Gene analysis tools version 10.0 
(http://www.pantherdb.org/tools) [31]. Furthermore, DAVID online tools were applied for the GO 
and KEGG pathway enrichment analyses with a p value set to < 0.05 (according to Benjamini-
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Hochberg correction) were considered significantly enriched. 
Because of a lack of strand specificity in the sequencing protocol, for the analysis of 
lncRNAs, only intergenic RNAs and antisense RNAs were selected — annotated in Ensembl v70 
— excluding transcripts showing overlap with protein coding genes. Transcriptional start sites 
(TSSs) of lncRNAs and protein-coding genes were downloaded from Ensembl v70 annotation, 
using the tool Table Browser of UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgTables) 
[32]. Differentially expressed lncRNAs, between LV tissues from HF vs. HD samples, were 
associated with the nearest TSS of protein coding genes using the function “closestBed” of 
BEDTools [33] with default parameters.  
 
Data validation by qRT-PCR and statistical analysis  
One microgram of total RNA, from patients and HD, was reverse-transcribed to cDNA 
using the SuperScript® IV (Invitrogen), following the manufacturer’s protocol. Primer sequences 
and corresponding polymerase chain reaction (PCR) conditions are shown in the Table S1 (see 
journal website, supplementary file). Gene expression was quantitatively determined by 
quantitative real-time PCR (qRT-PCR) analysis (detailed in Supplementary Methods — see 
journal website). Results were analyzed by threshold cycle (Ct) approach and normalized to 
RPS18, used as housekeeping gene [34]. Relative expression levels of the target genes were shown 
as fold change (FC), calculated through the 2–ΔΔCt method [34]. Results are reported as mean ± SE 
of three single experiments. Differences between experimental groups were analyzed by the 
ANOVA and t Student’s tests, considering significant a p value < 0.05 (*) and particularly 
significant a p < 0.01 (**). 
 
Results 
Transcriptome analysis of cardiac tissues  
This pilot study investigates the changes occurring in the transcriptome of cardiac tissues in 
HF patients and healthy subjects by RNA-Seq technology. Clinical characteristics of individuals are 
reported in Table 1. We isolated total RNA from LV myocardium of patients with DCM and RCM 
obtained at the time of heart transplantation. Control samples were obtained from transplant donor 
hearts. The cause of death in these individuals was road accident. All HD had no history of 
myocardial disease or active infections or significant comorbidities, such as hypertension, diabetes 
and hypercholesterolemia at the time of transplantation. Three of four subjects were female (77%) 
with a mean age of 58 ± 11.7 years. Donors and recipients were of Caucasian ethnicity. 
Globally, RNA-Seq produced paired-end reads with a sufficient quality and read coverage 
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per sample to perform reliable gene expression analysis (Fig. S1A–C — see journal website) [35]. 
The expression levels of protein-coding and non-coding genes have been analyzed for all samples. 
Multidimensional scaling analysis confirmed high correlation and reproducibility among individual 
samples of each group (Fig. S1D — see journal website). PCA revealed that the two different 
groups of patients, with different HF etiology (DMC/RCM), significantly differed (Fig. S1E — see 
journal website). RNA-Seq revealed that about 15,800 genes (Ensembl v70) were expressed in 
heart specimens and about 500 of them are currently annotated as lncRNAs by the GENCODE 
Consortium. As the classification of lncRNAs is far from complete and most of these transcripts 
overlap protein-coding loci, the focus was specifically on the long intergenic RNAs (lincRNAs) and 
antisense lncRNAs that can be unequivocally quantified by RNA-Seq. As a general observation 
there were significant differences between HF and HD transcriptomes, an attempt was made to 
identify genes with differential expression that were potentially associated with disease etiology. 
 
Significant alterations in the protein-coding transcriptome of HF vs. HD 
RNA-SeqGUI allows virtually quantifying all expressed genes in a cell or tissue [15]. The 
initial determination for each sample was the expression level of 56,622 loci (Ensembl v70), then 
the focus turned to the identification of DEGs between the groups under evaluation. First, we 
compared the gene expression profiles of HF vs. HD; next, DCM vs. HD; finally, RCM vs. HD 
subjects. 
Data analysis revealed that 2,428; 470 and 3,685 genes were significantly altered in the three 
groups, respectively (Fig. 1A). The degree of differential expression was variable and ranged from 
+6.3 to –5.3 log2FC between HF and HD; from +10.6 to –5.5 log2FC between DCM and HD and 
from +6.4 to –5.9 log2FC between RCM and HD. Most of DEGs (about 78%, 61%, and 65%, 
respectively) were significantly overexpressed in HF, DCM, and RCM patients, indicating a strong 
induction in gene transcription. As shown in Table 2, the HAPLN1 gene is always up-regulated 
when HF was analyzed, DCM and RCM groups (log2FC = +6.3; +6.2 and +6.4, respectively). 
Furthermore, the two most up-regulated genes were: CFAP61 and COL9A1 (log2FC = +4.6 and 
+4.5) in HF group; MTRNR2L1 and MYOZ1 (log2FC = +10.6 and +5.3) in DCM group; and 
CFAP61 and COL9A1 (log2FC = +5.0 for both genes) in RCM group. Similarly, the three most 
down-regulated genes were TRAJ39, TRAJ49, and CTRB1 (log2FC = –5.3; –4.7 and 4.7) when HF 
vs. HD was analyzed; TRAJ39, CTRB1, and CXCL14 (log2FC = –5.5; –4.9 and –4.6) in DCM vs. 
HD; and RSPO4, EDN2, and SELE (log2FC = –5.9; –5.7 and –5.7) in RCM vs. control group 
(Table 2). 
Interestingly, RNA-Seq analysis revealed the differential expression of 5 genes encoding 
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different subunits of the mediator complex (MED): MED12, MED13L, MED14, MED17, MED23 
(Fig. 1B; Table 3) (see the discussion section below).  
 
Gene ontology and KEGG pathway enrichment analysis of DEGs 
DAVID, Venny and Pathway analysis tools were used to determine molecular processes and 
biological pathways associated with the DEGs detected. We first associated differentially expressed 
mRNAs with three structured networks: biological process (BP), molecular function (MF) and 
cellular component (CC) in HF patients only (Tables S2–S5 — see journal website, 
supplementary file). Results showed a significant enrichment (p < 0.05 adjusted by the accepted 
Benjamini-Hochberg correction method) of particular biological processes when specific genes 
were altered. In particular, bioinformatic analysis revealed a significant alteration of “focal 
adhesion”, “regulation of actin cytoskeleton” and “oxidative phosphorylation” (adjusted p values 
5.64–11, 2.30–1 and 1.27–12, respectively) (Fig. 1C).  
The GO analysis further validated this experimental set up, demonstrating that many 
biological processes and molecular functions, already associated with HF, were also enriched in 
these datasets, including “cell-adhesion”, “cell-proliferation”, “cell-differentiation”, “transcription”, 
“apoptosis”, “proteolysis”, etc. (Fig. 1D; Tables S2–S5). Next, by KEGG pathway analysis found a 
number of biological pathways characterized by up- or down-regulated genes when under 
comparison (Fig. 2). The predominant up- and down-regulated pathways are summarized in Table 
S5, including related genes (345 up- and 239 down-regulated), and top 10 are represented in Figure 
2A, B. Specific DEGs of the first two classes significantly altered are shown in Figure 2C–E (up-
regulated DEGs) and Figure 2D–F (down-regulated DEGs).  
Based on Pubmed literature, some genes which had not been previously reported showed an 
association with human heart tissue. Among them, for instance, ADAMTS8 and ADAMTSL4 were 
localized predominantly in plasma cells and lung tissue (Table S6 — see journal website, 
supplementary file) [36]. ADAMTS8 and ADAMTSL4 genes were particularly down-regulated in 
HF vs. HD (–4.54 fold; false discovery rate [FDR] < 0.05 and –2.62 fold; FDR < 0.05 respectively). 
Both genes and many others in GO categories constitute an extremely rich source for potential 
target genes in HF understanding and prevention (Tables S2–S5). In addition, KEGG analysis 
demonstrated that several pathways were also altered in HF compared to HD; particularly in Figure 
3A, were shown “cell adhesion molecules” pathway and graphically, heatmaps were also reported 
(Fig. 3B–C) of “focal adhesion” (39 up- and 9 down-regulated genes) and “cardiac muscle 
contraction” (3 up- and 20 down-regulated genes) significantly altered in all HF patients (Fig. 3A–
C; Table S5). Finally, in order to identify a potential disease-specific signature, gene expression 
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levels were compared in DCM and RCM groups. The Figure S1D–E (see journal website, 
supplementary file) shows the PCA of the distinct considered groups: DCM and RCM compared 
to HD, providing a quick display of overall variability in screening and can highlight inconsistent 
samples. 114 genes were found in which expression was significantly altered between the two 
conditions, using mean gene expression values of HD as the background condition (Fig. S2A–C — 
see journal website, supplementary file). As shown in Figure S2D clusters of disease-specific 
genes belonging to the “TNF signaling pathway”, “phagosome”, “cytokine-cytokine receptor 
interaction” were identified. 
In the analysis of DCM vs. HD, DEGs were 470 ranging between FC = –5.5 (like TRAJ39 
gene) and FC = +10.6 (MTRNR2L1 gene). Of all DEGs about 61% (285 genes) were up-regulated 
and 39% (185 genes) were down-regulated. In analysis of RCM vs HD, DEGs were 3,685 ranging 
between a FC = –5.9 (like RSPO4 gene) and FC = +6.4 (HAPLN1 gene). Of all DEGs about 65% 
(2,390 genes) were up-regulated and 35% (1,295 genes) were down-regulated.  
The similarly of HF vs. HD comparisons, DCM and RCM DEGs compared to non-failing 
hearts were examined by GO and KEGG enrichment analyses separately. DEGs with higher 
expression levels in DCM were enriched for “cardiovascular” (p = 5.0 × 10–5) in disease class and 
were enriched for “cardiac muscle contraction” (p = 2.0 × 10–6) in KEGG pathway. The GO 
analysis showed that the DEGs clustered in MF, BP, and CC and were significantly enriched for 
terms related to “extracellular region” (p = 1.6 × 10–13) and “cell junction” (p = 3.3 × 10–4). 
Similarly, DEGs with higher expression levels in RCM were enriched for “cardiovascular” (p = 2.4 
× 10–12) in disease class. Instead, KEGG analysis was significantly enriched for “focal adhesion” (p 
= 1.6 × 10–3) and “ECM-receptor interaction” (p = 2.9 × 10–3). Finally, GO analysis showed that 
RCM DEGs clustered in MF, BP, and CC and were significantly enriched for terms related to “cell 
adhesion molecules” (p = 3.9 × 10–3) and “cardiac muscle contraction” (p = 1.3 × 10–2). 
 
Transcriptome analysis of failing hearts identifies differentially expressed lncRNAs 
Since lncRNA are emerging as crucial contributors to human diseases, the aim of this 
investigation was whether these non-coding RNAs may potentially have a role in HF. Therefore a 
systematic analysis of RNA-Seq datasets to identify lncRNAs differentially expressed was 
undertaken (DE) in HF vs. HD. In this data-driven analysis. Focus was mainly on intergenic and 
antisense lncRNAs, which do not overlap protein-coding loci and that can be unambiguously 
quantified using RNA-Seq. Differential expression analysis revealed that 140 lncRNA were 
significantly deregulated in HF vs HD. Among them, 33 non-coding genes were up-regulated and 
107 were down-regulated (Fig. 3D; Table 4). As lncRNA may act to regulate gene expression of 
 10 
surrounding protein-coding genes, DE lncRNAs were associated, through an automatic 
computational pipeline, with the transcription start site of the nearest protein-coding gene. Of these, 
27 (24 up- and 3 down-regulated) lncRNAs were DE (Table 4). Interestingly, among the most 
altered lncRNAs/gene and lincRNA/gene pairs we found EPHA5-AS1/EPHA5 and JAK1/RP11-
182I10 genes respectively. EPHA5-AS1 is located on chromosome 4q13.2 and Ensembl annotates 3 
different isoforms transcribed from this locus, with a long isoform composed of 4 exons (1,177 
nucleotide in length). Moreover, EPHA5-AS1 has a partial overlap with the 5’UTR of EPHA5 gene 
(Fig. 4A), suggesting a direct regulatory role of this antisense lncRNA on the sense protein-coding 
gene. To address whether a potential correlation may exist, normalized expression values of both 
the protein-coding and the lncRNA in all samples were compared. Interestingly, it was observed 
that both of them were significantly up-regulated in HF compared to HD (Fig. 4B), and the 
expression values had a high positive correlation (Pearson’s coefficient = 0.89). Also similarly 
revealed, was a positive correlation between JAK1 and RP11-182I10, a lincRNA/mRNA 
transcribed in the same orientation of JAK1 gene and was localized very close to this gene (Fig. 
4C). Boxplots in Figure 4D show the expression values of both genes under two different 
conditions (FDR < 0.05). 
 
RNA-Seq validation 
To validate the results of the analysis between two conditions, qRT-PCR on the same RNAs 
used for RNA-Seq experiments were performed (Table S1). Under analysis was the expression of 
several selections of significantly altered genes, including all GO categories, comparing HF and HD 
groups (Tables S2–S5). Particularly, altered cytoskeletal components, closely involved in the 
regulation of the actin and myosin cytoskeleton and muscle contraction, included: ACTA2, 
ACTG2, NMUR1, MYL4, and MYH10. Moreover, the following transcription factors involved in 
heart development and morphogenesis were selected: TBX20, SHOX2, HOPX and MSX1. 
Furthermore, among significantly DEGs, the retinoic acid producing enzyme ALDH1A2 was 
chosen for validation. Finally, among genes encoding for ionic channels, we selected: SLC8A1, 
CHRNE, HCN2, BDKRB2, and CACNA1G.  
All DEGs analyzed by qRT-PCR confirmed the expression trends obtained by RNA-Seq 
analysis. In Figure S3 observation revealed that FC measured by RNA-Seq (CPM) was confirmed 
also by qRT-PCR (2–ΔΔCt). 
 
Discussion 
Although a limited number of patients participated, the main findings of the present study 
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were: 
1) The identification of specific changes occurring in the transcriptome of HF patients compared to 
healthy subjects. In particular, bioinformatic analysis revealed a significant alteration of “focal 
adhesion”, “regulation of actin cytoskeleton” and “oxidative phosphorylation” in HF 
cardiomyocytes; 
2) The identification of some genes, which had not been previously reported, had an association 
with human heart tissue and HF (ADAMTS8, ADAMTSL4, ACTA2, ACTG2 and NMUR1); 
3) The identification of a potential disease-specific signature, comparing gene expression levels in 
DCM and RCM groups, revealing as significantly DEGs, genes belonging to the “TNF signaling 
pathway”, “phagosome”, “cytokine-cytokine receptor interaction”; 
4) The identification of altered levels of genes encoding 5 MED subunits that play a fundamental 
role in human HF. Among these, to date, MED17 has not yet been associated with CVD; 
5) The identification of specific non-coding RNAs that potentially have a role in HF. Focusing 
mainly on intergenic and antisense lncRNAs, differential expression analysis revealed that EPHA5-
AS1/EPHA5 and JAK1/RP11-182I10 genes (a lncRNAs/gene and lincRNA/gene pairs respectively) 
were significantly deregulated in HF vs. HD. 
Cardiomyocyte cytoskeleton is essential to maintain cell morphology and regulate 
contraction and relaxation. Alterations in cytoskeletal components have been found in both animal 
models of HF and in humans [37, 38]. Specifically, an increase in cytoskeletal proteins together 
with a loss of contractile filaments has been suggested as the morphological cause of heart 
dysfunction [37, 38]. The number of genes involved in this structural disruption continues 
increasing; however, other cytoskeleton and contractile fiber genes are expected to play a role in 
these pathologies. As previously reported, most genes encoding components for a wide variety of 
cellular compartments and pathways, such as: contractile and transduction apparatus, gene 
transcription and splicing machinery, and calcium regulation, were associated with DCM [11]. An 
example of altered genes, also deregulated in this condition and was represented by ACTC1, DSG2, 
MYH6, SGCD (Tables S2–S5). On the other hand, genetic mutations in familial RCM are not well 
defined, since there is significant overlap in the mutations between RCM, DCM, and HCM [12]. 
Also in RCM, accordingly to previous studies and presently identified genes encoding sarcomere 
(e.g. ACTC1, MYH7, and TNNT2), Z-disk proteins (e.g. MYPN), and intermediate filament 
network (e.g. DES) (Tables S2–S5). Interestingly, in the present study, a large number of genes 
were identified that had not been previously correlated with HF. Although the specific GO 
category/term is strongly associated with this pathology, significantly altered genes were found 
associated to “myocardial infarction susceptibility” and “cardiomyopathy” only when  down-
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modulated genes were considered. DEGs were also significantly enriched in “immune response” 
and “inflammation-related” pathways. Furthermore, other genes involved in “angiogenesis” and 
“cytoskeleton” were significantly altered in HF vs. HD as well as some genes with very important 
biochemical/biological functions in other tissues or organs (Table S6). The list of genes includes: 
ACTA2, NMUR1, ACTG2, KCNJ5, GATA6, MSX1, ZNF385B, ADAMTS8, ADAMTSL4 and 
COMP. In particular, ACTA2 and ACTG2 have been associated with HF for the first time in this 
study. Specifically, these genes were down-regulated both in DCM and RCM conditions. In the 
analysis of DCM and RCM vs. control group, ACTA2 gene reported a FC = –2.7 and –3.3, 
respectively. This trend was also confirmed for ACTG2, with a FC = –8.2 and –7.5 in DCM and 
RCM, respectively. As previously reported, these genes encode highly conserved molecules 
belonging to the actin family proteins, involved in cell motility, structure and integrity of the 
contractile apparatus [39]. Noteworthy, NMUR1 gene is particularly down-regulated in HF (–3.78 
fold; FDR < 0.05); this gene is endogenously expressed in adult rat cardiomyocytes, where it is 
involved in modulating L-type Ca(2+) channels [40]. Thus, this study suggests that the altered 
levels of NMUR1 may also play a significant role in human HF. 
Generally, the findings of this study indicate a more complex transcriptome alteration in 
RCM compared to DCM. Indeed, in DCM filtered list a total of 50 genes which were differentially 
expressed whereas RCM tissues displayed 516 common DEGs. Nevertheless, despite the different 
aetiologies of DCM and RCM, it is conceivable that both pathologies can share similar functional 
changes that are responsible for HF.  
Moreover, bioinformatic functional analysis demonstrated that DEGs binding-related genes 
(1,892 up-regulated and 536 down-regulated genes) were differentially expressed in failing samples 
when compared with non-failing hearts (Fig. 2A).  
Interestingly, our analysis also revealed the differential expression of 5 genes encoding 
various subunits of the MED: MED12, MED13L, MED14, MED17, MED23 when a PP > 0.95 was 
used to determine DEGs (Fig. 1B; Table 3). To date, alterations in MED complex genes have been 
associated with several human multifactorial diseases, including CVDs [41–44]. To date, only 
MED17 has not yet been associated with cardiovascular disease. All differentially expressed MED 
were up-regulated in HF patients. In particular, MED12 expression was found altered in DCM and 
RCM groups when we used a PP > 0.80. Noteworthy, MED17 gene is up-regulated in RCM 
patients (+0.50 fold; FDR < 0.05); this gene constitute a subunit of MED head module and interact 
with Pol II and the general transcription factors for both transcription and nucleotide excision repair 
mechanisms [45]. Thus, our pilot study suggests that the altered levels of MED subunits may play a 
fundamental role in human HF. In particular, since that MED complex has been also shown to work 
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in cooperation with ncRNAs in regulating gene transcription [41], it would be relevant to 
investigate MED17 functions in order to understand its role in the onset and progression of RCM.  
To date, several reports indicate that other classes of RNAs, other than protein-coding, are 
potential contributors to human diseases [46, 47], mainly as they are able to regulate gene 
expression at the transcriptional, post-transcriptional, and epigenetic levels [48, 49]. Among these 
ncRNAs, the class of lncRNAs plays an important role in several conditions such as cancer, liver 
disease and central nervous system disorders among many others. Exploratory studies performed on 
the lncRNA in the cardiovascular setting have thus far identified only few lncRNA associated with 
cardiovascular diseases [50, 51]. Specific studies looking at lncRNAs in HF remain lacking [51].  
To investigate whether lncRNAs may potentially have a role in heart diseases,  systematic 
analysis of RNA-Seq datasets to identify lncRNAs DE in HF was performed. Differential 
expression analysis revealed 140 significantly deregulated lncRNA in HF vs. HD. Among them, 
24% of non-coding genes were up-regulated and 76% were down-regulated. A searched for all the 
140 DE lncRNAs the nearest protein-coding genes and we could find only 27 pairs of lncRNA-
genes that are both differentially expressed was done. Of all, 27 genes (about 20%) were DE (Table 
4). Interestingly, among associated DE lncRNAs and protein coding genes, we found EPHA5-AS1 
(annotated also as RP11-807H7.1), a lncRNA transcribed antisense to EPHA5 gene. Both the 
protein-coding and the lncRNA are up-regulated in HF vs. HD (Fig. 4). Moreover, EPHA5-AS1 has 
a partial overlap with the 5’UTR of EPHA5 gene (Fig. 4), which suggests a direct regulatory role of 
this antisense lncRNA on the sense protein-coding gene. Ephrin receptors have diverse activities, 
including widespread effects on the actin cytoskeleton, cell-substrate adhesion, intercellular 
junctions, cell shape, and cell movement [52]. However, this is the first report about its deregulation 
in cardiomyopathies. 
Similarly, a positive correlation between JAK1 and the lincRNA RP11-182I10 was 
observed. Different from EPHA5-AS1, RP11-182I10 is transcribed on the same strand of JAK1 
gene in a typical head-to-tail orientation (Fig. 4C). The expression values of both genes under two 
different conditions were also increased (FDR < 0.05) (Fig. 4D). JAK1 gene encodes a protein-
tyrosine kinase member, operating fundamental roles as the intracellular signaling effector of 
cytokine receptors. The activation and/or inactivation of members of the Janus kinase family are 
causally linked to different human diseases, as hemopoietic malignancies, immunodeficiency and 
inflammatory diseases [53]. However, EPHA5 and the JAK1 gene have never been identified as 
altered in patients with cardiomyopathies. These novel changes could be responsible for altered 
contraction and cell disruption in HF subjects, which may suggest novel therapeutic approaches. 
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Conclusions 
The present findings revealed specific expression pattern of both protein-coding and 
lncRNAs in HF patients, confirming that new LV myocardial biomarkers could be reliably 
identified using Next-Generation Sequencing-based approaches. 
For patients awaiting heart transplantation, there are differences in survival on the basis of 
type of heart disease (DCM or RCM). The knowledge of an expression network signature in end-
stage HF diseased hearts may offer important insights into the complex pathogenesis of advanced 
cardiac failure, it may also provide potential targets for therapeutic intervention. 
All the novel changes revealed could be responsible for altered contraction and cell 
disruption in HF subjects. However, many of these factors, play critical roles in heart development 
and homeostasis as well as in other human diseases, an original list of novel candidate genes with 
potential implications in HF is offered. These findings reveal a specific expression pattern of both 
protein-coding and lncRNAs in HF patients, confirming that new LV myocardial biomarkers can be 
reliably identified using NGS-based approaches. Interestingly, for many of these proteins; 
pharmacological agonists and antagonists could be developed, raising exciting possibilities for new 
therapeutic approaches. 
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Table 1. Demographic and clinical characteristics of patients affected by cardiomyopathy 
Characteristics Donors data Recipients data 
Subjects  4 4 
Gender female  3/4 (77%) 2/2 (50%) 
Age [years]  57.5 ± 11.7 57.5 ± 10.2 
Waiting time on transplantation list [months] Accidental death 10 ± 10.3 
Body mass index [kg/m2]  26.4 ± 4.2 27.1 ± 3.3 
Serum creatinine [mg/dL]  1.32 ± 0.2 1.4 ± 0.1 
Total cholesterol [mg/dL] 152.0 ± 30.4 177.0 ± 43.0 
Low density lipoprotein [mg/dL] 96.50 ± 32.2 108.2 ± 27.7 
Diabetes No No 
Statin treatment No No 
Smoking No No 
Data are mean values ± standard deviation. 
 
 
Table 2. Top 10 up-regulated and down-regulated genes 
HF top 10 DEGs DCM top 10 DEGs RCM top 10 DEGs 
Up-regulated log2FC Up-regulated DEGs log2FC Up-regulated DEGs log2FC 
HAPLN1 6.31 MTRNR2L1 10.56 HAPLN1 6.41 
CFAP61 4.64 HAPLN1 6.21 CFAP61 5.05 
COL9A1 4.54 MYOZ1 5.32 COL9A1 5.00 
MYOZ1 4.47 FOSB 4.49 CENPA 4.08 
HAND1 4.39 HAND1 4.20 KIAA1211 4.07 
KIAA1211 3.84 CFAP61 4.05 ASB18 3.96 
UNC80 3.83 SYT12 3.92 UNC80 3.86 
TNN 3.76 COL9A1 3.85 RHCG 3.80 
COMP 3.71 UNC80 3.81 COMP 3.69 
CENPA 3.65 COMP 3.73 WBSCR17 3.55 
Down-regulated log2FC Down-regulated log2FC Down-regulated log2FC 
TRAJ39 –5.30 TRAJ39 –5.55 RSPO4 –5.92 
 19 
TRAJ49 –4.72 CTRB1 –4.94 EDN2 –5.74 
CTRB1 –4.72 CXCL14 –4.59 SELE –5.70 
PGA4 –4.57 TRAJ49 –4.36 MYOG –5.40 
ADAMTS8 –4.54 PGA5 –4.20 GDA –5.34 
PGA5 –4.51 PGA3 –4.15 PGA4 –5.31 
PGA3 –4.50 PGA4 –4.08 ADAMTS8 –5.24 
GJD2 –4.49 ADAMTS8 –4.07 TRAJ49 –5.21 
EDN2 –4.20 GJD2 –4.07 ADAMTS4 –5.20 
ETNPPL –3.89 NMUR1 –3.88 MT1A –5.17 
HF — heart failure; DCM — dilated cardiomyopathy; DEGs — differentially expressed gene; 
RCM — restrictive cardiomyopathy 
 
 
Table 3. Differentially expressed genes of mediator subunits in heart failure (HF) versus heart 
donor (HD) comparison. 
Mediator subunit HD HF 
MED1 15.23 18.80 
MED4 21.87 21.40 
MED6 9.45 9.90 
MED7 9.95 8.56 
MED8 19.33 18.15 
MED9 38.19 34.63 
MED10 19.88 16.74 
MED11 11.23 10.78 
MED12 22.26 33.96 
MED13 15.34 19.67 
MED13L 14.21 24.12 
MED14 19.77 28.94 
MED15 50.06 52.49 
MED16 30.56 23.39 
MED17 15.07 20.73 
MED18 9.38 8.78 
MED19 8.57 7.51 
 20 
MED20 13.49 12.50 
MED21 27.18 22.09 
MED22 27.09 26.63 
MED23 8.23 13.93 
MED24 58.19 64.20 
MED25 51.35 33.88 
MED26 3.94 4.52 
MED27 13.41 11.23 
MED28 16.27 16.33 
MED29 34.59 36.30 
MED30 5.94 5.95 
MED31 3.07 3.04 
CDK8 8.29 11.83 
CCNC 15.90 18.48 
Gene expression values of mediator complex subunits expressed in counts per million (CPM). 
Differentially expressed gene of mediator complex subunits are shown in bold red color.  
 
 
Table 4. Long non-coding RNAs differentially expressed (DE) in heart failure versus heart donor 
groups. 
DE lncRNA 
DE associated-
protein-coding 
gene 
lncRNA log2FC 
Protein-coding 
log2FC 
RP11-427H3 AAK1 1.25 1.34 
LINC00342 ANKRD36C 0.87 0.85 
LUCAT1 ARRDC3 -1.34 0.81 
LINC00900 CADM1 1.28 1.06 
SFTA1P CELF2 2.57 0.50 
RP11-261C10 CEP170 0.95 0.72 
RP11-807H7 EPHA5 1.20 1.27 
RP11-479J7 FAM78B –3.28 –3.07 
GDNF-AS1 GDNF 2.58 1.84 
RP11-441O15 GOT1 1.30 –0.32 
 21 
AC018647 HERPUD2 2.10 0.52 
RP11-182I10 JAK1 1.10 0.39 
AC096574 LRRFIP1 1.81 0.59 
CROCCP2 NBPF1 0.60 0.55 
RP11-121C2 NFXL1 1.14 –2.70 
LINC01011 NQO2 0.72 –0.51 
AC010096 OSR1 0.65 –1.43 
RP11-33B1 PDE5A 1.06 0.65 
RP11-10L7 PPM1K 1.39 1.42 
RP11-1114A5 RBMX 0.75 0.38 
NEAT1 SLC25A45 –0.47 1.01 
RP11-480A16 TNK2 0.82 0.77 
RP11-1275H24 TNRC18 0.62 0.61 
USP46-AS1 USP46 0.89 0.95 
OVAAL XPR1 1.60 1.31 
MIRLET7DHG ZNF169 0.97 1.01 
RP11-457M11 ZNF322 0.97 0.93 
lncRNA — long noncoding RNA 
 
 
 
Figure 1. Analysis of differentially expressed genes in heart failure and heart donor groups. A. 
Volcano plot reporting on the y axis 1-P (posterior probability) in log10 scale and on the x axis 
log10FC (fold change calculated as disease/healthy samples). Genes identified as significantly 
differentially expressed (PP > 0.95) are shown as red dots; B. Scatter plot of normalized (counts per 
million [CPM]) MED gene expression values. Each circle represents a unique gene encoding a 
mediator complex family member. Black circles indicate differentially expressed gene (DEGs); C, 
D. Bar graph reporting the results of the “Pathway” and “Gene Ontology MF” analysis used to infer 
the function of DEGs identified by RNA sequencing. Categories are reported on the x axis, DEGs’ 
number on the y axis. 
 
 
Figure 2. Pathway analysis of the top 10 significantly altered genes; A, B. Pathway analysis of the 
top 10 significantly changed up- and down-regulated differentially expressed gene (DEGs) (dots 
 22 
and stripes respectively) when comparing heart failure and heart donor. In the panels C/E and D/F 
are reported specific up- and down-regulated DEGs (dots and stripes respectively) of the first and 
second more abundant pathway. 
 
 
Figure 3. Pathways most affected in heart failure (HF) versus heart donor (HD) from RNA 
sequencing analysis. A. Graphical representation of the KEGG pathway “Cell adhesion molecules”. 
Red boxes indicate genes down-regulated in HF, green the ones up-regulated. “Focal adhesion” and 
“cardiac muscle contraction” pathway are reported in the panels B and C as heatmaps (with the 
hierarchical clustering option). The degree of differential expression between the two HF and HD 
groups is indicated by a three-color code (down-regulated genes are depicted in red, up-regulated 
genes in green and genes with little-to-none variation are indicated in black). Similarly, panel D 
shows the heatmap (with the hierarchical clustering option) of long non-coding RNAs differentially 
expressed in HF versus HD samples. 
 
 
Figure 4. Genomic localization of differentially expressed antisense long noncoding RNA 
(lncRNAs); panels A (EPHA5/EPHA5-AS1) and C (JAK1/RP11-182I10) show the schematic 
graphical representations of lncRNA/mRNA and long intergenic RNAs (lincRNAs)/mRNA pairs 
(RefSeq genes) that are significantly altered in heart failure patients. In panels B and D the 
expression levels (normalized values, counts per million [CPM]) of both the gene and the neighbor 
lncRNA associated to it (Pearson’s coefficient = 0.89) are reported (FDR < 0.05). 
 




